Board meet on 4 November 2026 to consider Q2 results, RTA change and initial fund-raise proposal
Tavexia Lifecare has informed BSE that its Board meets on Wednesday, 4 November 2026.
By ScoutQuest · · 2 min read
- Board Meeting Date
- Wednesday, 4 November 2026
- Results Period
- quarter and half-year ended 30 September 2026
- Trading Window Closure
- until 48 hours after the results are declared
What the exchange intimation says
The company has given prior notice of a Board of Directors meeting scheduled for Wednesday, 4 November 2026, under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice lists four items of business.
- Financial results: to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026, along with the Limited Review Report of the Statutory Auditors.
- Registrar and Share Transfer Agent: to consider and approve a change of the company's RTA and take the necessary steps, subject to applicable regulatory and other approvals, wherever required.
- Fund raising: to discuss and approve the initial proposal for fund raising by issue and allotment of securities (Equity/Warrants) through a preferential issue, rights issue or other mode.
- Any other matter, with the permission of the Chair.
Trading window
The trading window for dealing in the company's securities will remain closed for all designated persons and their immediate relatives until 48 hours after the financial results for the quarter and half-year ended 30 September 2026 are declared. This is under the company's Code of Conduct for Prevention of Insider Trading.
What each item means for a shareholder
- Results are the regular quarterly and half-yearly numbers. The standalone and consolidated sets, plus the auditors' limited review, are the standard disclosure package for a listed company.
- An RTA handles share transfer, demat and investor-record work. A change of RTA is an administrative step; the notice says it is subject to applicable regulatory and other approvals, wherever required. The name of the incoming RTA is not part of this notice.
- The fund-raising item is described as an "initial proposal" and covers Equity/Warrants through a preferential issue, rights issue or other mode. The amount, price, number of securities and the mode are not part of this notice; the Board is meeting to discuss and approve the proposal. Any such issue would carry its own separate disclosure and approval process.
Things to keep in view
- The notice is an intimation of what the Board will consider. It is not the outcome of the meeting.
- The fund-raising item is a proposal to be discussed; the terms will be known only from what the company discloses after the meeting.
- The trading window closure applies to designated persons and their immediate relatives, not to the general public.
Put together, the notice points to a results announcement, an administrative change of registrar and a first look at a possible fund raise, all at one meeting on 4 November 2026.
Also from Tavexia Lifecare
Board approves Q2 results; in-principle nod to raise up to ₹68 crore for proposed 60% acquisition
4 Nov 2026
Consolidated results for the 30.09.2026 Unaudited
4 Nov 2026
Board gives in-principle nod to raise up to Rs. 68 crore for 60% Meyonex stake; H1 shows a loss
4 Nov 2026
More numbers
- Trading window closure after results declaration48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.